Management of VEGFR-Targeted TKI for Thyroid Cancer

Recent advances in the development of multitarget tyrosine kinase inhibitors (MTKIs), which mainly target the vascular endothelial growth factor receptor (VEGFR), have improved prognoses and dramatically changed the treatment strategy for advanced thyroid cancer. However, adverse events related to t...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Tomohiro Enokida, Makoto Tahara
Format: article
Langue:EN
Publié: MDPI AG 2021
Sujets:
Accès en ligne:https://doaj.org/article/d297a4b93e314faa9394fbab99a5b059
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!